The decrease in hepatic lipid accumulation and inflammation in response to implantation of the NRIP1 depleted adipocytes suggests that this therapeutic approach might mitigate these T2D co-morbidities in humans36. This evidence concerns the gene NRIP1 and type 2 diabetes mellitus.